Analyst Price Targets — NSPR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 1:55 pm | Frank Takkinen | Loop Capital Markets | $5.00 | $1.82 | StreetInsider | Lake Street Capital Markets Reiterates Buy Rating on InspireMD (NSPR) |
| February 2, 2026 12:44 pm | — | Maxim Group | $6.00 | $1.68 | TheFly | InspireMD initiated with a Buy at Maxim |
| December 11, 2024 1:48 pm | Frank Takkinen | Lake Street | $5.00 | $3.17 | TheFly | InspireMD initiated with a Buy at Lake Street |
| September 17, 2024 7:17 am | Adam Maeder | Piper Sandler | $4.50 | $2.61 | StreetInsider | Piper Sandler Reiterates Overweight Rating on InspireMD (NSPR) |
Latest News for NSPR
InspireMD, Inc. (NSPR) Q4 2025 Earnings Call Transcript
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.19 per share a year ago.
MIAMI, March 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the fourth quarter and year ended December 31, 2025. Recent Business Highlights: Generated revenue of $3.1 million in the fourth quarter of 2025, up 62% year-over-year.
MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial…
MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to one (1) new non-executive employee in the aggregate amount of 36,118 shares of restricted stock (the “Inducement Grants”)…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NSPR.
U.S. House Trading
No House trades found for NSPR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.